help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakaoka, D.
Right arrow Articles by Chihara, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakaoka, D.
Right arrow Articles by Chihara, K.
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 5 1901-1907
Copyright © 2000 by The Endocrine Society


Original Studies

Prediction of Bone Mass Change after Parathyroidectomy in Patients with Primary Hyperparathyroidism1

Daiki Nakaoka, Toshitsugu Sugimoto, Tatsuya Kobayashi, Toru Yamaguchi, Akira Kobayashi and Kazuo Chihara

Third Division, Department of Medicine, Kobe University School of Medicine (D.N., T.S., T.K., T.Y., K.C.), Kobe 650-0017; and Kuma Hospital (A.K.), Kobe 650-0011, Japan

Address all correspondence and requests for reprints to: Toshitsugu Sugimoto, M.D., Third Division, Department of Medicine, Kobe University School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.

A major challenge in the management of primary hyperparathyroidism (pHPT) is the decision regarding which patients should undergo parathyroidectomy (PTX), although the Consensus Development Conference of the NIH has proposed guidelines for the indication of surgery. In the present study, changes in bone mineral density (BMD) after PTX were compared between pHPT patients who did and did not meet the NIH criteria, and we further tried to predict the BMD change after PTX from preoperative parameters. The subjects were 44 pHPT patients (30 women and 14 men) who had had successful PTX. Lumbar and radial BMD were measured before and 1 yr after PTX by dual energy x-ray absorptiometry and single photon absorptiometry, respectively. Average annual percent increases in lumbar and radial BMD after PTX were 12.2 ± 1.4% and 11.6 ± 1.6% (mean ± SEM), respectively, and those net increases were 0.0803 ± 0.0008 and 0.0484 ± 0.0006 g/cm2, respectively. There were no significant differences in percent or net changes in either radial or lumbar BMD after PTX between the groups divided according to each of the NIH criteria, such as age (>=50 and <50 yr), serum calcium level (>=12 and <12 mg/dL) or the existence of urinary stones (presence and absence). On the other hand, when the subjects were divided on the basis of radial BMD (above and below a z-score of -2), the annual percent and net increases in lumbar BMD and percent increase in radial BMD after PTX were significantly higher in the group with the lower z-score. Next, patients were divided into two groups with and without the indication of PTX based on NIH guidelines. Twenty-nine patients had the surgical indication by meeting one or more of these criteria and 15 patients had no indication without meeting any of the criteria. There were no significant differences between the two groups in annual percent or net changes in radial or lumbar BMD after PTX. A stepwise multiple regression analysis revealed that serum alkaline phosphatase level and the severity of cortical bone mass reduction were the best predictors of both percentage and net changes in lumbar BMD, with high determination coefficients (r2 > 0.7). In conclusion, a considerable increase in BMD could be obtained after PTX even in patients without surgical indication from the NIH. Alkaline phosphatase and the severity of cortical bone mass reduction are clinically useful for predicting the changes in lumbar BMD after PTX. The present findings provide a useful clue for the indication of surgery in pHPT.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
C. C. Chow, W. B. Chan, J. K. Y. Li, N. N. Chan, M. H. M. Chan, G. T. C. Ko, K. W. Lo, and C. S. Cockram
Oral Alendronate Increases Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism
J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 581 - 587.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
M. Peacock, C. H. Turner, M. J. Econs, and T. Foroud
Genetics of Osteoporosis
Endocr. Rev., June 1, 2002; 23(3): 303 - 326.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society